High Throughput Screening with AstraZeneca's Compound Library
The Academic Drug Discovery Consortium (ADDC) has an established screening partnership with AstraZeneca (AZ). This a partnership provides selected ADDC members access to a high quality compound library and allows AstraZeneca the opportunity to access and collaborate with academic researchers with novel disease targets of interest and priority to the company.
This RFP seeks applications from institutions performing drug discovery and who are interested in screening compounds provided by AstraZeneca. The screening library will be provided free-of-charge to the selected proposals. AstraZeneca also offers the possibility of support of approximately $20k to $40k, which may come, in part, in the form of reagents and other material support.
Three specific libraries are available for collaboration. First is a 250,000 diversity set which provides a broad representation of AstraZeneca's industry-leading compound collection. Also available are a 14,000 annotated set covering 1200 human targets with at least 100 nM potency at the primary target and a low molecular weight fragment screening set of 17,000 compounds.
Certain target proposals may be excluded if there are pre-existing contractual obligations or areas where AstraZeneca already has existing programs within the company.
Centers who want to take part in this screening collaboration should submit a five (5) page proposal covering the below areas.
1. Target background and rationale
2. Target validation (pharmacological and/or genetic)
3. Potential clinical utility
4. Currently available tool compound for the target
5. Funding for screen and hit follow-up
6. Competitive landscape
7. High Throughput Screening Readiness
i. HTS assay description
iii. Pilot screening data, if available
8. Plans for Hit confirmation/validation once hits are obtained
9. Drug discovery screening flow chart
10. Facilities description:
i. Ability to conduct HTS
ii. Ability to conduct Structure Activity Relationship (SAR) studies on the screening hits NIH Type Biosketch of Investigators
The dates will be announced for each round. A Steering committee comprising of ADDC members and Astra Zeneca will prioritize and review the proposals. Please email Matthew Hartman to request a copy of Appendix A: IP Guidelines.
Academic Drug Discovery Consortium
For more information on Partnering With AstraZeneca https://www.astrazeneca.com/Partnering.html